Patents by Inventor Mark Andrew Wortinger

Mark Andrew Wortinger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GITR antagonists and methods of using the same
    Patent number: 11859005
    Abstract: The present disclosure relates to compounds that bind to human GITR, pharmaceutical compositions comprising such compounds, and methods of using such compounds.
    Type: Grant
    Filed: February 1, 2022
    Date of Patent: January 2, 2024
    Assignee: Eli Lilly and Company
    Inventors: Petra Verdino, Paul Francis Cain, Melinda Ann Lacerte, Stacey Lynn Lee, Mark Andrew Wortinger
  • c-Met antibodies
    Patent number: 8398974
    Abstract: Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: March 19, 2013
    Assignee: Eli Lilly and Company
    Inventors: Julian Davies, Ling Liu, Jirong Lu, Peter Edward Vaillancourt, Mark Andrew Wortinger, Wei Zeng
  • c-Met Antibodies
    Publication number: 20120263723
    Abstract: Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.
    Type: Application
    Filed: June 25, 2012
    Publication date: October 18, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Julian Davies, Ling Liu, Jirong Lu, Peter Edward Vaillancourt, Mark Andrew Wortinger, Wei Zeng
  • c-Met antibodies
    Patent number: 8217148
    Abstract: Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.
    Type: Grant
    Filed: November 18, 2009
    Date of Patent: July 10, 2012
    Assignee: Eli Lilly and Company
    Inventors: Julian Davies, Ling Liu, Jirong Lu, Peter Edward Vaillancourt, Mark Andrew Wortinger, Wei Zeng
  • c-Met Antibodies
    Publication number: 20100129369
    Abstract: Provided are monoclonal antibodies, antigen-binding fragments thereof, and combinations of the foregoing, that bind to, and inhibit the activity of, c-Met, and that are effective in treating cancers and other diseases, disorders, or conditions where pathogenesis is mediated by c-Met.
    Type: Application
    Filed: November 18, 2009
    Publication date: May 27, 2010
    Inventors: Julian Davies, Ling Liu, Jirong Lu, Peter Edward Vaillancourt, Mark Andrew Wortinger, Wei Zeng